Get started
Author

Paul Machui

Institution: Tubulis (Germany)
ORCID: 0009-0006-7772-2361
Observed ORCID: 0009-0006-7772-2361
OpenAlex ID: A5086653125
Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile
2023 · Philipp Ochtrop, Jahaziel Jahzerah, et al. · Chemical Science · 37
PDF
Enantioselective Biocatalytic Reduction of 2H-1,4-Benzoxazines Using Imine Reductases
2018 · Nadine Zumbrägel, Paul Machui, et al. · The Journal of Organic Chemistry · 33
Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
2023 · Saskia Schmitt, Paul Machui, et al. · Molecular Cancer Therapeutics · 25
PDF
Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates
2026 · Philipp Ochtrop, Anil P. Jagtap, et al. · Nature Communications · 9
PDF
TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al. · Molecular Cancer Therapeutics · 7
PDF
Abstract 2622: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans
2024 · Saskia Schmitt, Isabelle Mai, et al. · Cancer Research · 7
Abstract 2623: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index
2024 · Saskia Schmitt, Isabelle Mai, et al. · Cancer Research · 3
Supplementary Table 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Table 2 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 10 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 5 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 4 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 6 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 3 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 7 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Methods 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 8 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 2 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 9 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Data from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Abstract 7018: Antibody-degrader conjugates unlock the therapeutic potential of heterobifunctional degraders through antibody-like pharmacokinetics and excellent in vivo efficacy
2025 · Jan G. Felber, Anil P. Jagtap, et al. · Cancer Research
Supplementary Data from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
2024 · Saskia Schmitt, Paul Machui, et al.
Supplementary figure 3 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
2024 · Saskia Schmitt, Paul Machui, et al.
Supplementary figure 2 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
2024 · Saskia Schmitt, Paul Machui, et al.
Works count: 37
Citation count: 121
H-index: 6
I10-index: 3
Year
Topic
Type